Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

A Multi-centre, Open, Randomised, Parallel, Controlled Trial to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin With Insulin Alone in Type 2 Diabetic Subjects Inadequately Controlled With Sulphonylurea ± Biguanide Therapy

This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

Inclusion Criteria:

• HbA1c between 7.5 % and 13.0% (both inclusive)
• Fasting C-peptide above or equal to 0.33 nmol/l
• BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive)

Exclusion Criteria:

• Medical history of treatment with insulin within the last 6 months
• Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 µmol/l)